BMRN Price Prediction Next Week
Analysis and Insights
Fundamental Analysis:
BioMarin Pharmaceutical (BMRN) has shown strong financial performance, with a trailing four-quarter earnings surprise of 32.4% on average. The company has a solid pipeline, including Voxzogo, which has seen significant global uptake. BMRN's financial health is further supported by its strong interest coverage ratio and positive EPS growth projections for 2025 and 2026.
Technical Analysis:
The stock is currently trading near the middle of its Bollinger Bands, with the price at $69.01. The RSI (14) is at 53.38, indicating the stock is not overbought or oversold. The MACD is slightly positive, suggesting a bullish trend.
Recent News and Analyst Sentiment:
Oppenheimer recently upgraded BMRN to "Outperform" with a $98 price target, citing strong Q4 results and confidence in the company's long-term outlook. This, combined with the stock's recent uptrend, suggests positive momentum.
Price Prediction:
Based on the analysis, the stock is expected to rise. The target price for the next trading week is $76.04.
Recommendation:
Buy BMRN at the current price of $69.01, targeting $76.04.
BMRN Similar Chart Price Prediction
The price of BMRN is predicted to go up 0.56%, based on the high correlation periods with ECC. The similarity of these two price pattern on the periods is 98.37%.
BMRN
ECC
BMRN Revenue Forecast
BMRN EPS Forecast
BMRN FAQs
What is BMRN revenue forecast for next quarter？
The market consensus for BMRN's revenue in the upcoming quarter is projected to be approximately $741.095M USD.
What is BMRN eps forecast for next quarter？
BMRN VS S&P500
BioMarin's approved drugs have been granted orphan-drug status in the US and EU, providing them with at least 7 and 10 years of market exclusivity, respectively.
BioMarin's drugs target rare chronic conditions that often require treatment from a very young age, and while locating eligible patients on a global level is challenging, the firm has high patient retention rates.
With a growing portfolio in an attractive rare-disease niche-and acceleration of profit growth beginning in 2022-BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill.
BMRN Analyst's Forecast
Leland Gershell
Oppenheimer
2025-02-24
Price Target
$98
Upside
+41.99%
George Farmer
Scotiabank
2025-02-20
Price Target
$78 → $80
Upside
+16.04%
David Lebovitz
Citigroup
2025-02-20
Price Target
$81 → $82
Upside
+18.94%
